JPMorgan analyst Rohin Patel downgraded Haemonetics (NYSE: HAE) from Overweight to Neutral with a price target of $62.00 (from $85.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE